## REGN: Regeneron Pharmaceuticals, Inc. - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_10 at 4.0% in lower entry zone (3.0-6.0%), top quartile (87th pct) cross-sectional ranking. Short-term MRS_5 (1.4%) confirms momentum alignment. Strong momentum (+5.9% 5-day acceleration). Outperforming sector by 4.0%.

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($702.88)
- **If Wrong:** Exit if MRS_10 drops below entry zone or breaks stop
- **Invalidation:** MRS_10 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 8
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Westwood Holdings Group Inc. Grows Position in Regeneron Pharmaceuticals, Inc. $REGN**
- Source: MarketBeat | 20251216T134409 | Bullish | Relevance: 100%
- Westwood Holdings Group Inc. increased its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 17.0% in Q2, acquiring an additional 1,974 shares to own a total of 13,556 shares valued at $7.12 million. This move is part of a broader trend of institutional accumulation, with institutions now holding approximately 83.31% of the stock. Regeneron Pharmaceuticals has also received multiple analyst upgrades, leading to a "Moderate Buy" consensus rating and an average price target of $779.45.

**2. Stock Watch: Regeneron Caught Between Success And Expiry**
- Source: Citeline News & Insights | 20251216T121552 | Neutral | Relevance: 100%
- This article examines Regeneron Pharmaceuticals, highlighting its position between past successes and impending patent expiries. Andy Smith provides a life science investor's perspective on the biopharma business challenges faced by Regeneron.

**3. Praxis Investment Management Inc. Has $762,000 Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN**
- Source: MarketBeat | 20251216T120852 | Somewhat-Bullish | Relevance: 100%
- Praxis Investment Management Inc. significantly reduced its stake in Regeneron Pharmaceuticals (NASDAQ:REGN) by 55.3% in Q3, now holding 1,355 shares valued at $762,000. Despite this, Regeneron exceeded Q3 earnings and revenue estimates, reporting an EPS of $11.83 on revenues of $3.75 billion. The company maintains a "Moderate Buy" consensus rating from analysts with a target price of $779.45.

**4. MASTERINVEST Kapitalanlage GmbH Makes New $1.14 Million Investment in Regeneron Pharmaceuticals, Inc. $REGN**
- Source: MarketBeat | 20251215T120813 | Somewhat-Bullish | Relevance: 100%
- MASTERINVEST Kapitalanlage GmbH has initiated a new $1.14 million investment in Regeneron Pharmaceuticals, Inc. by purchasing 2,168 shares. Other institutional investors have also adjusted their positions in the biopharmaceutical company, reflecting broad investor interest. Regeneron reported strong quarterly earnings, beating analyst estimates, and announced a quarterly dividend.

**5. Alvotech Launches $100 Million Senior Unsecured Convertible Bond Offering to Continue Strong Investment in R&D, Support Manufacturing, Global Product Launches and Enhance Liquidity Position, reaffirms 2025 outlook and provides 2026 guidance**
- Source: Yahoo Finance UK | 20251216T165035 | Somewhat-Bullish | Relevance: 63%
- Alvotech has launched a $100 million senior unsecured convertible bond offering to fund continued strong investment in R&D, manufacturing, and global product launches, while also enhancing its liquidity position. The company reaffirmed its 2025 financial outlook, projecting revenues between $570-$600 million and adjusted EBITDA of $130-$150 million, and provided 2026 guidance with anticipated revenues of $650-$700 million and adjusted EBITDA of $180-$220 million, even considering potential FDA approval delays. This strategic move aims to maintain Alvotech's lead in biosimilar development and launch new products globally.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 6, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-12 | Morgan Stanley | $768 | $767 | +0% |
| 2025-12-10 | Wells Fargo | $745 | $700 | +6% |
| 2025-12-04 | Canaccord Genui | $1057 | $850 | +24% |
| 2025-12-04 | BMO Capital | $850 | $725 | +17% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-12 | Morgan Stanley | main | Equal-Weight |
| 2025-12-10 | Wells Fargo | main | Equal-Weight |
| 2025-12-04 | Canaccord Genui | main | Buy |
| 2025-12-04 | BMO Capital | main | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 9 ($97.67M) |
| Sells | 15 ($32.83M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 44.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 8.8% (-4.0%)
- Blackrock Inc.: 8.6% (-4.7%)
- JPMORGAN CHASE & CO: 7.9% (+106.7%)
- State Street Corpora: 4.5% (-2.9%)
- Dodge & Cox Inc.: 4.4% (+18.9%)

### Key Risks

1. Heavy insider selling: $33M sold (15 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 6 raises (avg +13%) could attract flows.
- New product launch cycle could drive revenue acceleration.
- Momentum building: MRS_10 improving +5.9% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 1.46 suggests fair value with growth premium. Quality metrics strong (margin 32%). Balance sheet: strong liquidity (4.1x), low leverage (D/E 0.30), $1.4B free cash flow. Analyst sentiment positive (6 raises, avg +13%). Insider buying signal ($97.7M), management confidence. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $79.1B |
| Beta | 0.37 |
| 52W Range | $476.49 - $790.98 |
| Short Interest | 3.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.46 |
| Forward P/E | 19.5 |
| Current P/E | 17.3 |
| YoY Growth | -11.2% |
| EPS Direction | RISING |

### Technicals

MRS_10 strengthening from -1.9% to 4.0% (+5.9% in 5 days), confirming momentum buildup. Currently in lower STRENGTH zone (3.0-6.0%), cross-sectional ranking at 87th percentile. MRS_5 at 1.4% confirms short-term momentum alignment. Outperforming sector by 4.0pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-3.64), momentum weakening. RSI neutral at 59. OFD pattern: -SLL (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 3.98% (CS: 88) | Strong |
| RSI_14 | 59.2 | Neutral |
| MACD Histogram | -3.64 | Bearish |
| vs SMA20 | 1.009x | Above |
| vs SMA50 | 1.119x | Above |
| vs SMA200 | 1.244x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $746.36
- **Stop Loss:** $702.88 (5.8% risk)
- **Target:** $811.58 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 22
- **Position Value:** $16,419.92
- **Portfolio %:** 16.42%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with balanced risk positioning. VIX remains calm at 16.48 while breadth shows modest improvement to 52%, indicating neither euphoria nor distress. Mixed sectoral themes from energy weakness to AI expansion suggest stock-picking environment rather than broad directional moves.*

### Earnings

**Next:** 2026-02-03 (Est: $10.77)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $9.64 | $11.83 | +22.7% |
| 2025Q2 | $8.44 | $12.89 | +52.7% |
| 2025Q1 | $8.48 | $8.22 | -3.0% |
| 2024Q4 | $11.19 | $12.07 | +7.8% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*